{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/cervical-screening/management/managing-hpv-cervical-cytology-results/","result":{"pageContext":{"chapter":{"id":"cb3f22ee-57b6-5cf4-aed8-3471ae0e9a9c","slug":"managing-hpv-cervical-cytology-results","fullItemName":"Scenario: Managing HPV and cervical cytology results","depth":2,"htmlHeader":"<!-- begin field 2af4dba6-0200-4dde-8f44-b4713aa549b3 --><h2>Scenario: Managing HPV and cervical cytology results</h2><!-- end field 2af4dba6-0200-4dde-8f44-b4713aa549b3 -->","summary":"Covers the management of HPV cervical cytology results, when to refer women to colposcopy, and the management of incidental infection.","htmlStringContent":"<!-- begin item 8d353c48-df37-4783-b723-d0ebba0ecda1 --><!-- begin field ddb31c9d-348d-481f-953b-acbc01573bea --><p>From age 25 years to 65 years (Female).</p><!-- end field ddb31c9d-348d-481f-953b-acbc01573bea --><!-- end item 8d353c48-df37-4783-b723-d0ebba0ecda1 -->","topic":{"id":"6eb2d6d6-d121-574a-8070-e380a54d0dd0","topicId":"7394dee4-4555-4874-bb15-5ac5d86ed7d9","topicName":"Cervical screening","slug":"cervical-screening","lastRevised":"Last revised in September 2020","chapters":[{"id":"2fe43b2a-0956-5a22-a141-2c23ff8702d1","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5da2ce64-4373-5a2d-a1a6-3f3bbdf2bf7c","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7b70a539-14d0-50b6-93cc-edbf89ec4bc3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"576d9368-458f-5490-8bdf-666b91a7e37a","slug":"changes","fullItemName":"Changes"},{"id":"bcd50065-ad13-5af2-8473-de68a499f070","slug":"update","fullItemName":"Update"}]},{"id":"c2a0a95f-2a9b-5c96-a2b0-d26471380d35","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8e98fda8-7c58-5f08-8d78-770e7406cc2b","slug":"goals","fullItemName":"Goals"},{"id":"aac1adb6-9e3a-50e6-976b-3d8be05b4f28","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b4286b35-0cba-5c8d-b4c0-55905649e5ef","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"32c01e99-78fd-50ce-a1b4-3fd4edcb1ecb","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d0510235-ec88-5b0a-9a2e-4ad7888d78be","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"5c4e6833-b040-537b-a32b-54b1317aa217","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b8be2709-4f11-5914-bcf3-e1a1d79fd23f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"6d7d120d-e785-5601-9d0e-e08e28d89528","slug":"cervical-screening-programme","fullItemName":"Cervical screening programme"},{"id":"b6a7bd00-5536-5a5d-b7f3-fe1ac9685d22","slug":"cervical-screening-system","fullItemName":"Cervical screening system"}]},{"id":"5cc77439-27cd-51ff-9a06-857c9da72416","fullItemName":"Management","slug":"management","subChapters":[{"id":"ba0780ef-6124-5552-b202-75eebabe99e3","slug":"cervical-screening","fullItemName":"Scenario: Cervical screening"},{"id":"cb3f22ee-57b6-5cf4-aed8-3471ae0e9a9c","slug":"managing-hpv-cervical-cytology-results","fullItemName":"Scenario: Managing HPV and cervical cytology results"}]},{"id":"a5410c1d-84f3-5826-8512-481fd075d2a9","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5aade9cf-191d-5481-a6fc-cc57568100f2","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2e666af8-5f3b-576d-b97c-d4a65b6bb80e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"b3806c5f-8045-5cf8-a395-aea0d965082b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"df251649-2597-5c2e-8fb1-5740228d0346","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"58fed207-e499-59b9-99ec-0b1dd974fe5e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"26cba24b-2a00-54c4-b253-3e851f0fbcba","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7cf3b493-5fcc-5741-878b-5f094a762815","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"5cc77439-27cd-51ff-9a06-857c9da72416","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"ed2683dc-ed19-5fef-8f2d-299a352ab791","slug":"hpv-results","fullItemName":"HPV results","depth":3,"htmlHeader":"<!-- begin field 6609ae8d-6f4b-41f2-9b8a-ac3000b257a7 --><h3>What should happen following HPV results?</h3><!-- end field 6609ae8d-6f4b-41f2-9b8a-ac3000b257a7 -->","summary":null,"htmlStringContent":"<!-- begin item cb8526c6-9f4c-49f5-b3d1-73dac720d91e --><!-- begin field 722239b3-cad7-4e9c-acc0-ac3000b257a7 --><ul><li>Individuals who receive a negative result can be safely returned to routine recall unless on:<ul><li>The test of cure (TOC) pathway.</li><li>The untreated CIN1 pathway.</li><li>Follow-up for incompletely excised cervical glandular intraepithelial neoplasia (CGIN), stratified mucin producing intraepithelial lesion of the cervix (SMILE) or cervical cancer.</li><li>Follow-up for borderline changes in endocervical cells.</li></ul></li><li>Management of individuals who are positive for high-risk human papillomavirus (hrHPV) is determined by <a class=\"topic-reference internal-reference\" href=\"/topics/cervical-screening/management/managing-hpv-cervical-cytology-results/#cytology-results\">cytology results</a>.</li></ul><!-- end field 722239b3-cad7-4e9c-acc0-ac3000b257a7 --><!-- end item cb8526c6-9f4c-49f5-b3d1-73dac720d91e -->","subChapters":[{"id":"50c27738-8ced-5d54-a5db-adf767ae3987","slug":"basis-for-recommendation-1ba","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field bd7b312d-d4cd-4545-b0ec-ac3000b257a7 --><h4>Basis for recommendation</h4><!-- end field bd7b312d-d4cd-4545-b0ec-ac3000b257a7 -->","summary":null,"htmlStringContent":"<!-- begin item 1ba18d12-5859-498d-9451-417710425c08 --><!-- begin field 6ab9e7fc-8842-409d-9c48-ac3000b257a7 --><p>These recommendations are based on the Public Health England (PHE) guidance <em>Cervical screening: programme and colposcopy management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-screening/references/\">PHE, 2020</a>].</p><!-- end field 6ab9e7fc-8842-409d-9c48-ac3000b257a7 --><!-- end item 1ba18d12-5859-498d-9451-417710425c08 -->","subChapters":[]}]},{"id":"2ba9d31f-531f-543e-8ad7-41f474eed3d9","slug":"cytology-results","fullItemName":"Cytology results","depth":3,"htmlHeader":"<!-- begin field 0f9ef5f1-59f4-41f7-9725-8c107c410ebe --><h3>How are cytology results reported?</h3><!-- end field 0f9ef5f1-59f4-41f7-9725-8c107c410ebe -->","summary":null,"htmlStringContent":"<!-- begin item 0fb4ef44-ae87-4d71-a43b-1e4020733e18 --><!-- begin field ef667022-c82b-4e33-810b-5b064f58f331 --><ul><li><strong>Inadequate </strong>— this may be because the cervical sample:<ul><li>Was taken but the cervix was not fully visualized.</li><li>Was taken in an inappropriate manner (for example, using an unapproved device).</li><li>Contains insufficient cells.</li><li>Contains an obscuring element (for example lubricant, inflammation, or blood).</li><li>Is incorrectly labelled.</li></ul></li><li><strong>Negative </strong>— no abnormality is detected.</li><li><strong>Abnormal </strong>— the cervical samples may show:<ul><li><strong>Borderline changes in squamous or endocervical cells.</strong></li><li><strong>Low-grade dyskaryosis.</strong></li><li><strong>High-grade dyskaryosis (moderate).</strong></li><li><strong>High-grade dyskaryosis (severe).</strong></li><li><strong>Invasive squamous cell carcinoma.</strong></li><li><strong>Glandular neoplasia.</strong></li></ul></li></ul><!-- end field ef667022-c82b-4e33-810b-5b064f58f331 --><!-- end item 0fb4ef44-ae87-4d71-a43b-1e4020733e18 -->","subChapters":[{"id":"dc4821eb-b22f-5607-a6e6-72c65693f830","slug":"basis-for-recommendation-91b","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 473207cf-197c-4e89-b237-441bbe7d3975 --><h4>Basis for recommendation</h4><!-- end field 473207cf-197c-4e89-b237-441bbe7d3975 -->","summary":null,"htmlStringContent":"<!-- begin item 91b13c06-92b9-4134-b6bc-267231bd7d22 --><!-- begin field 85857505-c061-43b5-9cb5-bb0c587b9f59 --><p>These recommendations are based on the Public Health England (PHE) guidelines <em>NHS Cervical screening programme: guidance for the training of cervical sample takers</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-screening/references/\">PHE, 2016a</a>] and <em>NHS cervical screening programme: colposcopy and programme management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-screening/references/\">PHE, 2016b</a>], and the British Medical Journal (BMJ) best practice guide <em>Abnormal pap smear</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-screening/references/\">BMJ, 2016</a>].</p><!-- end field 85857505-c061-43b5-9cb5-bb0c587b9f59 --><!-- end item 91b13c06-92b9-4134-b6bc-267231bd7d22 -->","subChapters":[]}]},{"id":"38f59959-02db-5e78-8585-b84e88129012","slug":"managing-normal-results","fullItemName":"Managing normal results","depth":3,"htmlHeader":"<!-- begin field bcd4240c-0b5f-46e3-ae4d-967c46f88f7d --><h3>What should happen following a normal cervical cytology result?</h3><!-- end field bcd4240c-0b5f-46e3-ae4d-967c46f88f7d -->","summary":null,"htmlStringContent":"<!-- begin item 73a6bc9a-53df-44a9-8a76-3faae5595c54 --><!-- begin field 32121426-15f8-42a8-86c0-8577ae6e7e05 --><ul><li>Individuals who are positive for high-risk human papillomavirus (hrHPV) and receive a negative cytology report as part of routine primary HPV screening should have the HPV test repeated at 12 months.<ul><li>If HPV testing is negative at 12 months, individuals can be safely returned to routine recall.</li><li>Individuals who remain hrHPV positive, cytology negative at 12 months should have a repeat HPV test in a further 12 months.<ul><li>Individuals who become hrHPV negative at 24 months can be safely returned to routine recall.</li></ul></li><li>Individuals who remain hrHPV positive, cytology negative or inadequate at 24 months should be referred to colposcopy.</li></ul></li><li>Individuals who remain hrHPV positive with cytology reported as borderline dyskaryosis or worse at 12 or 24 months should be referred to colposcopy.</li></ul><!-- end field 32121426-15f8-42a8-86c0-8577ae6e7e05 --><!-- end item 73a6bc9a-53df-44a9-8a76-3faae5595c54 -->","subChapters":[{"id":"178ad56d-1416-538f-b713-5c7bad073671","slug":"basis-for-recommendation-880","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 82a0af18-5590-4f11-bda1-952b1807d7f9 --><h4>Basis for recommendation</h4><!-- end field 82a0af18-5590-4f11-bda1-952b1807d7f9 -->","summary":null,"htmlStringContent":"<!-- begin item 8803e241-7834-463f-b1ff-17176cfb9157 --><!-- begin field 70946b91-b59b-481b-b155-628240e09e67 --><p>These recommendations are based on the Public Health England (PHE) guidelines <em>NHS Cervical screening programme: guidance for the training of cervical sample takers</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-screening/references/\">PHE, 2016a</a>] and <em>NHS cervical screening programme: colposcopy and programme management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-screening/references/\">PHE, 2020</a>].</p><!-- end field 70946b91-b59b-481b-b155-628240e09e67 --><!-- end item 8803e241-7834-463f-b1ff-17176cfb9157 -->","subChapters":[]}]},{"id":"675ffadf-0cf6-5301-b110-e09523bcf8bd","slug":"managing-abnormal-results","fullItemName":"Managing abnormal results","depth":3,"htmlHeader":"<!-- begin field 9cd965c5-4769-4bab-a07c-23d5e565ff75 --><h3>What should happen following an abnormal cervical cytology result?</h3><!-- end field 9cd965c5-4769-4bab-a07c-23d5e565ff75 -->","summary":null,"htmlStringContent":"<!-- begin item 12318520-66fe-4321-a6f1-b51f10e82df4 --><!-- begin field 0cc2a8ff-916c-4e97-aeb9-4079623f27ca --><ul><li><strong>All individuals who are positive for high-risk human papillomavirus (hrHPV) and have abnormal cytology are referred to colposcopy. </strong></li><li><strong>Ensure the person has received an explanation about what an abnormal result means and what further tests or treatment may be needed.</strong><ul><li>The NHS Cervical Screening Programme (NHSCSP) provides the leaflets <a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/598278/cervical_screening_leaflet.pdf\" data-hyperlink-id=\"d41f3774-3253-4f83-8b1d-a98d005a1a00\">NHS cervical screening: helping you decide</a> and <a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/523376/Having_the_colposcopy_booklet.PDF\" data-hyperlink-id=\"c208b47c-84b9-48e5-8383-a98d005a1a29\">NHS cervical screening: having a colposcopy</a>.</li><li>The NHS website (<a href=\"https://www.nhs.uk/\" data-hyperlink-id=\"956bce7f-b27d-4098-b66d-a98d005a1a52\">www.nhs.uk</a>) provides information on the <a href=\"https://www.nhs.uk/conditions/cervical-screening/\" data-hyperlink-id=\"71a1c45a-d184-4c61-ba95-a98d005a1aac\">Cervical screening test</a> and <a href=\"https://www.nhs.uk/conditions/cervical-screening/your-results/\" data-hyperlink-id=\"0e9227c4-ace9-4a27-a430-a98d005a1add\">Cervical screening - Results</a>.</li></ul><strong> </strong></li></ul><!-- end field 0cc2a8ff-916c-4e97-aeb9-4079623f27ca --><!-- end item 12318520-66fe-4321-a6f1-b51f10e82df4 -->","subChapters":[{"id":"3f627f23-b380-558d-b919-1c553b4ddec7","slug":"colposcopy","fullItemName":"Colposcopy","depth":4,"htmlHeader":"<!-- begin field 01d7a5fa-8e73-401b-b84d-48b8fc612f28 --><h4>Colposcopy</h4><!-- end field 01d7a5fa-8e73-401b-b84d-48b8fc612f28 -->","summary":null,"htmlStringContent":"<!-- begin item f7dd4f2d-abfa-4c61-894f-a7ff49698f0b --><!-- begin field 0151a663-5089-445d-97c9-3a67a53205bc --><ul><li><strong>At colposcopy the cervix is assessed in detail using a colposcope.</strong></li><li><strong>The colposcopist:</strong><ul><li>Looks for any abnormal changes in the cervix which may indicate pre-cancerous changes (cervical intraepithelial neoplasia [CIN]) or the presence of cancer.</li><li>Usually applies chemicals to the cervix, for example:<ul><li>If acetic acid is applied to the cervix, abnormal areas (such as CIN) tend to turn white (sometimes referred to as acetowhite).</li><li>If an iodine solution is applied, normal tissue (on the outside of the cervix) stains dark brown. Pre-cancerous abnormalities may not stain with iodine. The cells on the inner part of the cervix do not stain brown.</li></ul></li><li>May take a biopsy to confirm the diagnosis.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-screening/references/\">British Society for Colposcopy and Cervical Pathology, 2013</a>]</p><!-- end field 0151a663-5089-445d-97c9-3a67a53205bc --><!-- end item f7dd4f2d-abfa-4c61-894f-a7ff49698f0b -->","subChapters":[]},{"id":"514d8969-8e2a-5d93-90a8-5774af46870b","slug":"basis-for-recommendation-344","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field f08f263a-3760-4dfe-878f-53169143de66 --><h4>Basis for recommendation</h4><!-- end field f08f263a-3760-4dfe-878f-53169143de66 -->","summary":null,"htmlStringContent":"<!-- begin item 34432517-d14f-47f4-9a5b-478a6a47f3e9 --><!-- begin field 8f4af618-1643-40a0-9ecb-1fb06b23cd45 --><p>These recommendations are based on the Public Health England (PHE) guidelines <em>NHS Cervical screening programme: guidance for the training of cervical sample takers</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-screening/references/\">PHE, 2016a</a>] and <em>NHS cervical screening programme: colposcopy and programme management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-screening/references/\">PHE, 2020</a>], and what CKS considers to be good clinical practice.</p><!-- end field 8f4af618-1643-40a0-9ecb-1fb06b23cd45 --><!-- end item 34432517-d14f-47f4-9a5b-478a6a47f3e9 -->","subChapters":[]}]},{"id":"59b1b4bb-212b-5c01-916a-1b24008f9c7e","slug":"managing-inadequate-samples","fullItemName":"Managing inadequate samples","depth":3,"htmlHeader":"<!-- begin field 3592b79c-43c1-4bf7-b930-eb007421bcef --><h3>What should happen if results are unavailable or if there is an inadequate cervical cytology sample?</h3><!-- end field 3592b79c-43c1-4bf7-b930-eb007421bcef -->","summary":null,"htmlStringContent":"<!-- begin item 42f8bd94-93ae-44c7-bafa-2f9e2f3eb888 --><!-- begin field 29a4e95d-1759-4c25-804f-9fb163ce5c1f --><ul><li>If the high-risk human papillomavirus (hrHPV) test result is unavailable or cytology is inadequate at any screening episode in the pathway — the sample is repeated in no less than 3 months.<ul><li>Individuals who have inadequate cytology at the 24 month repeat test are an exception — these people are referred to colposcopy. </li></ul></li><li>Individuals who have two consecutive HPV results unavailable or inadequate cytology results, in any combination are referred to colposcopy.<ul><li>Individuals who have a normal and adequate colposcopy examination should be followed up in the community at 12 months.<ul><li>If hrHPV testing is negative at 12 months, the individual is returned to routine recall.</li></ul></li><li>If colposcopy is inadequate, individuals should have a repeat screening test and colposcopy examination in 12 months.<ul><li>If the repeat colposcopy is normal and HPV negative, the individual is discharged to routine recall.</li></ul></li></ul></li></ul><!-- end field 29a4e95d-1759-4c25-804f-9fb163ce5c1f --><!-- end item 42f8bd94-93ae-44c7-bafa-2f9e2f3eb888 -->","subChapters":[{"id":"d61c91bd-710f-5604-862a-ea5869cd30d1","slug":"basis-for-recommendation-faf","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 61b33a59-731c-4822-a4eb-53a347058718 --><h4>Basis for recommendation</h4><!-- end field 61b33a59-731c-4822-a4eb-53a347058718 -->","summary":null,"htmlStringContent":"<!-- begin item faf31c62-6611-435a-95f4-a85591c958aa --><!-- begin field 9945a63b-1e31-4f4f-9e9f-da047ec3a873 --><p>These recommendations are based on the Public Health England (PHE) guideline <em>NHS cervical screening programme: colposcopy and programme management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-screening/references/\">PHE, 2020</a>].</p><!-- end field 9945a63b-1e31-4f4f-9e9f-da047ec3a873 --><!-- end item faf31c62-6611-435a-95f4-a85591c958aa -->","subChapters":[]}]},{"id":"0344b9f5-ab73-5b1d-ae34-e19493eb4966","slug":"managing-incidental-organisms","fullItemName":"Managing incidental organisms","depth":3,"htmlHeader":"<!-- begin field 951d900c-6f60-4ff1-a881-6848cdad6ceb --><h3>How do I manage someone who has organisms reported on their cervical cytology result?</h3><!-- end field 951d900c-6f60-4ff1-a881-6848cdad6ceb -->","summary":null,"htmlStringContent":"<!-- begin item 4b6c173f-0ca6-4e48-9341-eee59f9019b5 --><!-- begin field 79c984ae-a726-457d-87cb-de5d54143b61 --><ul><li><strong>If <em>Candida </em>is present, </strong>see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/candida-female-genital/\">Candida - female genital</a>.</li><li><strong>If bacterial vaginosis is present, </strong>see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/bacterial-vaginosis/\">Bacterial vaginosis</a>.</li><li><strong>If herpes simplex virus (HSV) is present, </strong>see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/herpes-simplex-genital/\">Herpes simplex - genital</a>.</li><li><strong>If <em>Trichomonas vaginalis </em>is present, </strong>see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/trichomoniasis/\">Trichomoniasis</a>.</li><li><strong>If actinomyces-like organisms (ALOs) are present:</strong><ul><li><strong>If the woman is asymptomatic:</strong><ul><li>If an intrauterine device (IUD) or the levonorgestrel intrauterine system (LNG-IUS) is in situ, it does not need to be removed.</li><li>No follow up is required.</li></ul></li><li><strong>If the woman is symptomatic. </strong>For example pelvic pain, deep dyspareunia, intermenstrual bleeding (six months after an intrauterine device has been inserted), vaginal discharge, dysuria, or significant pelvic tenderness:<ul><li>If an IUD or LNG-IUS is in situ, consider removing it. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/pelvic-inflammatory-disease/\">Pelvic inflammatory disease</a>.</li><li>Obtain endocervical swabs for <em>Chlamydia trachomatis </em>and <em>Neisseria gonorrhoeae</em>. For further information on the investigation of pelvic inflammatory disease, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/pelvic-inflammatory-disease/\">Pelvic inflammatory disease</a>.</li></ul></li></ul></li></ul><!-- end field 79c984ae-a726-457d-87cb-de5d54143b61 --><!-- end item 4b6c173f-0ca6-4e48-9341-eee59f9019b5 -->","subChapters":[{"id":"f27f8ee2-314e-506a-91bd-96ea44f61b4c","slug":"basis-for-recommendation-668","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 51ed26ea-a0ff-4408-b128-d622a890e4b1 --><h4>Basis for recommendation</h4><!-- end field 51ed26ea-a0ff-4408-b128-d622a890e4b1 -->","summary":null,"htmlStringContent":"<!-- begin item 66803f1e-6f1c-4031-8cb9-9a599956a233 --><!-- begin field 6c87851a-ad2c-4417-b2b8-08fa9d91ed69 --><p>These recommendations are based on the Public Health England (PHE) guideline <em>NHS cervical screening programme: colposcopy and programme management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-screening/references/\">PHE, 2016b</a>].</p><!-- end field 6c87851a-ad2c-4417-b2b8-08fa9d91ed69 --><!-- end item 66803f1e-6f1c-4031-8cb9-9a599956a233 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}